Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Cystic Neoplasms and Pancreatic Neuroendocrine Tumors

Inclusion Criteria: * Consensual indication to EUS-guided RFA treatment made in a multidisciplinary team * Capability of giving informed consent PCN Inoperability or refusal of surgery * Branch duct IPMN (BD-IPMN) with worrisome features: * Jaundice * High grade dysplasia or cancer * Solid mass/nodule \> 5mm * Main pancreatic duct dilation \> 10mm Or at least one (patients without comorbidities) or at least two (patient with comorbidities) of the following risk features: * CA 19-9\> 37 U/ml * Increase in size \> 5mm/year * Dilation of the main pancreatic duct between 5-10mm * Size ≥ 40mm * Symptoms (new onset of diabetes, acute pancreatitis) * Nodule \< 5mm Pancreatic NET * Size \< 2 cm * Histological proof in non-functional lesions/histological proof or clinical proof in functional lesions * 68Ga-DOTATATE PET/CT positive for a pancreatic lesion and negative for lymph nodes, liver, and other distant metastases * G1 or G2 (\<5 %) histology Exclusion Criteria: * Known bleeding disorder that cannot be sufficiently corrected with medication * Use of anticoagulants that cannot be discontinued * Physical and/or psychological inability to understand the aims of the research and to adequately cooperate * Pregnancy * Inability to sign the informed consent